Open access · CC-BY
via OpenAlex
How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story
Arlan G Richardson, Verónica Galván, Ai‐Ling Lin, Salvatore Oddo
Experimental Gerontology · 2014 · ▲ 125 citations
Abstract
The discovery that mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) increases lifespan in mice and restores/delays many aging phenotypes has led to the speculation that rapamycin has 'anti-aging' properties. The major question discussed in this review is whether a manipulation that has anti-aging properties can alter the onset and/or progression of Alzheimer's disease, a disease in which age is the major risk factor. Rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of Alzheimer's disease (AD-Tg) as well as reduce Aβ and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation. All of these parameters are widely recognized as symptoms central to the development of AD. Furthermore, rapamycin has also been shown to improve memory and reduce anxiety and depression in several other mouse models that show cognitive deficits as well as in 'normal' mice. The current research shows the feasibility of using pharmacological agents that increase lifespan, such as those identified by the National Institute on Aging Intervention Testing Program, to treat Alzheimer's disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.exger.2014.12.002
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Richardson, A.G., Galván, V., Lin, A., & Oddo, S. (2014). How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. <em>Experimental Gerontology</em>. https://doi.org/10.1016/j.exger.2014.12.002
Vancouver
Richardson AG, Galván V, Lin A, Oddo S. How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. Experimental Gerontology. 2014. doi:10.1016/j.exger.2014.12.002.
BibTeX
@article{arlan2014Howlon,
title = {How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story},
author = {Arlan G Richardson and Verónica Galván and Ai‐Ling Lin and Salvatore Oddo},
journal = {Experimental Gerontology},
year = {2014},
doi = {10.1016/j.exger.2014.12.002},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
GeroScience 2023
Preprint · OA
Rapamycin restores peripheral blood flow in aged mice and in mouse models of atherosclerosis and Alzheimer’s disease
Frontiers in Genetics 2025
Open access · CC-BY
Editorial: Genetic modulation of gut microbiome: effects on neurological health and aging
Neuropsychologia 2020
Preprint · OA
Beyond Alzheimer's disease: Can bilingualism be a more generalized protective factor in neurodegeneration?
medRxiv 2026
Open access · OA
Alzheimer’s disease blood biomarkers reveal proteomic modules of disease progression
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only